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Abstract
Arguments have been put forth as to whether women who donate oocytes for human embryonic
stem cell (HESC) research should be compensated, but data regarding this issue have been scant.
Recently in the United States, several States have begun funding HESC research, and patient
recruitment efforts have begun. This paper lays out relevant arguments and presents data
concerning this issue. Researchers are finding that women are unwilling to donate eggs
altruistically, which is hampering the progress of research. These efforts are examined, and data
on potential donors’ views are presented. The absence of payment, rather than ethical concerns,
appears to explain opposition to donation. Women also appear generally ignorant of policies in
this area. It is suggested that policy discussions shift focus from whether to pay, to how much
would be appropriate, and how to decide; and that research and public and professional education
be increased to heighten understanding and awareness of these issues.
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Introduction
Whether women who donate eggs for human embryonic stem cell (HESC) research should
be paid remains hotly debated in both Europe and the United States (USA), but scant
relevant data have been available. HESC research (see definitions in Materials and methods
for all abbreviations) more broadly has been one of the most controversial topics in
contemporary medical science, capturing the attention of scientists, physicians, politicians,
theologians and the lay public, all of whom struggle for consensus on how best to proceed in
the development and proper use of this research. Following early advancements with various
mammalian stem cell lines, concerns arose over the potential for misuse of stem cell
research, prompted particularly by questions of reproductive cloning. The lack of safeguards
led to governmental prohibitions that severely restricted or banned research outright. In the
USA, President Obama on March 9, 2009 reversed President George W Bush’s ban on the
use of federal monies to develop new cell lines beyond those already existing, which had
forced most researchers to pursue avenues outside traditional federal grants.
Philanthropically obtained funds and, recently, individual state grants, have in the meantime
secured the necessary capital for further development of this important research.
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The start of state funding of stem cell research in New York, California, Massachusetts and
elsewhere has strengthened the promise of establishing a successful research programme in
this area. However, clinical material available to researchers remains scarce. Somatic cell
nuclear transfer (SCNT) is best performed using fresh eggs that are enucleated so that a
desired somatic cell nucleus can be fused to create a unique cell line carrying the specific
traits desired for study. Although egg donation has been commonly used as an infertility
treatment in Europe and the USA for over 20 years, recruitment of women to provide
gametes for stem cell research has been discouraged through several sets of guidelines and
policies.
In the United Kingdom (UK), the Human Fertilisation and Embryology Authority (HFEA)
has permitted so-called ‘egg-sharing’, in which women undergoing their own IVF treatment
can donate extra eggs (for purposes of reproduction or research, albeit only in a licensed
research project), and receive their treatment for free or at reduced rates. Yet the HFEA has
prohibited payment to any other egg donors (Ramsey, 2007). Suggestions have also been
made to allow women in poorer countries to provide eggs to women in wealthier countries
through egg sharing in return for free or less expensive IVF treatment (Heng, 2005). Such
eggs from poorer countries could presumably also be used for research. Yet such
international marketing of embryos may pose particular ethical concerns, given cultural and
economic differences between countries. Moreover, importantly, the use of embryos
acquired through egg sharing usually does not advance research goals for SCNT, which
aims to produce disease-specific and patient-specific stem cells. Embryos remaining from
preimplantation genetic diagnosis (PGD) could produce disease-specific stem cell lines, but
have also been frozen, which probably impairs their usefulness; and unused embryos may
have been initially unselected because they appeared in fact less viable in morphology or
development. Hence, they may be less efficacious for research purposes, too.
In the USA, the National Academy of Sciences (NAS) stated that donors providing gametes
specifically for stem cell research should not receive compensation beyond reimbursement
for time and travel expenses (NAS, 2005, 2007, 2008). The California Institute for
Regenerative Medicine (CIRM, 2007) subsequently adopted this policy to govern payments
for potential egg donors, and will not accept eggs supernumerary for reproductive egg
donation cycles where donors received traditional compensation. CIRM’s decision may be
in response to arguments from two groups, religious conservatives urging that payment fails
to adequately respect human dignity, and certain feminists averring that payment represents
commodification of the body. Indeed, given that the risks and benefits of egg donation for
research purposes are not wholly clear, some critics have argued that a moratorium should
be placed on all egg donation for this purpose (Beeson and Lippman, 2006). Massachusetts,
which has similarly set aside funds for stem cell research, has also adopted the NAS policy,
which outlaws payment per se to donors.
In both Europe and the USA, several issues concerning payment for the procurement of eggs
for HESC have received some discussion (Hyun, 2006; Thompson, 2007), and arguments
for and against have been laid out (Okie, 2005; Robertson, 2006; Steinbrook, 2006; Ramsey,
2007; Spar, 2007), but unfortunately, most of these discussions took place before
researchers, funded by States and private philanthropy, began actual recruitment.
In the USA, recent state efforts, and initiation of actual recruitment and research are raising
and highlighting critical new challenges. In 2007, for example, New York pledged $600
million over 6 years, for stem cell research. President Obama’s reversal of President Bush’s
ban on federal funding makes reconsiderations of these issues even more urgent.
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Despite arguments in favour of compensation (Hyun, 2006; Thompson, 2007), opposition
continues, making it important to examine new relevant data, and reflect on why these
obstacles exist, and how to address them.
In 2007, the American College of Obstetrics and Gynecology (2006) and the American
Society for Reproductive Medicine (ASRM) (2007) guidelines endorsed reasonable payment
of donors for SCNT. The International Society for Stem Cell Researchers (ISSCR) also
opened the door to possible compensation, saying, “Reimbursement for direct expenses
incurred by donors as a consequence of the consent process may be determined during the
SCRO (Stem Cell Research Oversight) process (Ethics Committee, ASRM 2000; Daley et
al., 2007)”. Nevertheless, NAS, CIRM and Massachusetts policies remain unchanged.
Moreover, although New York has adopted ISSCR guidelines, final decisions are still left up
to local Embryonic Stem Cell Research Oversight (ESCRO) Committees. Questions then
arise as to how ESCRO Committees will in fact make these decisions. Institutional Review
Boards (IRB), for example, are known to vary widely (Klitzman, 2008).
Opponents argue that additional compensation may result in undue inducement and
exploitation (Beeson and Lippman, 2006; CIRM, 2007; Ramsey, 2007). Women may decide
to provide eggs primarily because of financial need, undervaluing the physical and
psychological risks of donation. Critics argue, too, that eggs should not be bought and sold
in the marketplace like other commodities, and that to do so represents a lack of dignity and
respect. Commentators have also argued (ASRM, 2000) that payment might decrease
altruistic donations; that poorer women might differentially donate; that blood and organ
donors are not likewise compensated; and as was mentioned above, that embryos could
alternatively be donated by women already undergoing IVF therapy.
Yet, on the other hand, compensation does not necessarily violate key underlying ethical
principles. Although egg donation appears to be a relatively safe procedure, women do face
some physical and psychological risks in donating oocytes, undergoing ovarian
hyperstimulation and egg retrieval, and are inconvenienced by weeks of required therapy.
Concerns remain as to whether exposures to gonadotrophins increase the incidence of
ovarian neoplasms and cancers (Mertes and Pennings, 2007), although well designed
retrospective studies have failed to document a relationship (Brinton et al., 2005; Kanakas
and Mantzavinos, 2006). Thus, payment may well be appropriate. Moreover, in the clinical
setting, donors are paid. Hence, for research subjects to receive a smaller payment than
individuals undergoing the same activities in the commercial sector is inequitable.
Restrictions based on fears of undue influence may themselves be paternalistic. US Federal
regulations prohibit, but do not define ‘undue inducement’ and ‘coercion’ (US Department
of Health and Human Services, 2005); and precise definitions of these terms remain unclear
(Ripley, 2006). Furthermore, critics have argued that IRB interpret these terms too broadly
and are overly concerned about coercion in research, which, these commentators maintain,
occurs rarely, if at all (Emmanuel, 2004). Indeed, no research has been published on whether
coercion actually occurs in current research, and if so, how often. Moreover, for women to
provide informed consent, respect of their autonomy in making their own informed choices
is itself very important. Although high payments, beyond a certain point, could potentially
become ethically problematic, that should not preclude other, lesser and more reasonable
amounts. Compensation for a woman’s expenses, ‘time, inconvenience and discomfort
associated with oocyte retrieval can also be distinguished from payment for the oocytes
themselves’ (ASRM, 2007).
Although blood and living organ donors are uncompensated, blood donation is minimally
risky, and living individuals who donate organs generally do so to close family members and
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loved ones. Thus, these examples do not wholly apply to the case of HESC research.
Importantly, despite arguments that payments may decrease altruistic donation, almost no
such donation has in fact yet occurred. In fact, researchers have experienced difficulties in
recruiting women to donate eggs for free. In larger centres, egg donors are available to
participate in stem cell research efforts without denying infertile couples interested in
accessing eggs an opportunity to receive these. To date, at Harvard, for example, years of
significant recruitment efforts and costly advertisements have generated interest from
hundreds of women, but when told they would not be compensated more than for direct
expenses, all but one potential donor declined to participate (Eggan, personal
communication). Yet one privately funded researcher who has paid donors (an average of
US$3673 per egg) has indeed been able to recruit donors (Vogel, 2006).
This lack of donors in the absence of compensation in and of itself indicates a need to revisit
this debate. Although critics have heretofore argued that donations could be obtained
without payment, researchers’ recent experiences reveal that prohibition of payment in fact
impedes scientific progress, raising more forcefully issues that need to be entered into the
debate concerning social benefit and social justice. Patients who might benefit from
treatments arguably may soon be delayed from receiving them because of prohibitions on
payment of donors. Providing fair compensation could thus offer important social benefits
by facilitating donation that could greatly advance the pace and success of research, leading
to treatments that can aid innumerable patients.
Further questions arise regarding how much egg donors do, or should get paid if payment
indeed becomes permissible. Of note, across all areas of medical research, uncertainties
persist about how much subjects do or should get paid, and few data are available on how
often participants in fact get compensated, how much, and how researchers, participants and
IRB view and approach these decisions. Varying models have been proposed to determine
appropriate amounts: a ‘market model’ (based on supply and demand, and potentially
providing more payment for subjects undertaking more risk), a ‘wage payment model’
(based primarily on providing a low, standardized wage that could be increased for
particularly uncomfortable or onerous tasks), and a ‘reimbursement model’ (covering
expenses, including opportunity costs from missed work) (Dickert and Gradey, 1999). In
practice, these models may not always be distinct, and whether and how often they are in
fact followed remains unknown. Only a handful of studies have been conducted on how
often study participants are actually paid. Recently, it was found that most published articles
fail to mention whether participants have in fact been paid, and if so, how much (Klitzman
et al., 2007). In at least two areas (diabetes and depression), most on-line recruitment sites
for research do compensate participants (Klitzman et al., 2008). Thus, in medical research
overall, major questions persist of not only whether, but how much participants are or
should be paid.
ASRM’s guidelines for compensation of egg donors endorsed the concept of fair payment,
initially with ceilings of US$5000, revised as the marketplace has altered rates of payment,
recommending most recently US$10,000 (ASRM, 2007). Indeed, a market model supports
paying the same as for egg donation for clinical purposes: typically US$2000–8000 (Kliff,
2007). Alternatively, a wage model could suggest that egg donors receive approximately the
same per hour as do sperm donors. Thus, a 1993 analysis suggested that if sperm donors
receive approximately US$25 for approximately 1 h, then oocyte donors, spending
approximately 56 h in procedures and counselling, should receive equivalent compensation
per hour, or US$1400 for egg donors (Siebel and Kiessling, 1993). By the year 2000, sperm
donors received approximately US$60–75, which would translate to up to approximately US
$4200. Today, sperm donors receive even more. Such a wage model, providing what many
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would see as a reasonable, but not excessive amount of compensation, would also offset the
possibility of recruiting only the poorest women.
Yet astonishingly, the views of women who may consider donation have been absent from
these debates. In fact, several feminist scholars have argued that these women’s voices are
important in these discussions (Dickenson, 2006). Surprisingly, no datum has been found on
how women either might donate eggs for reproductive purposes or, more broadly, view
these issues.
Hence, we decided to explore how women already enrolled as egg donors for reproductive
purposes perceive these questions: whether they would be willing to provide eggs for
research, and if so, whether they would do so without payment, and, if not, how much they
think would be appropriate.
Materials and methods
Definitions
ASRM = American Society for Reproductive Medicine; CIRM = California Institute of
Regenerative Medicine; ESCRO Committees = Embryonic Stem Cell Research Oversight
Committees; HESC = human embryonic stem cell; HFEA – Human Fertilization and
Embryology Authority; IRB = Institutional Review Board; ISSCR = International Society
for Stem Cell Researchers; NAS = National Academy of Science; PGD = preimplantation
genetic diagnosis; SCNT = somatic cell nuclear transfer; SCRO = Stem Cell Research
Oversight.
Survey procedure
In the past 5 years, over 1000 women have been screened, and over 250 have been enrolled
into the egg donor programme at Columbia University. Typically, Columbia University
performs around 100 egg donation attempts annually. Hence, many more potential donors
are screened than are actually employed. Usually, couples select egg donors of similar race,
religion or educational backgrounds to themselves. This study surveyed 230 consecutive
women enrolled or presently participating as egg donors in the Columbia University
programme for assisted reproduction, who now receive an US$8000 payment for this
service. Questions were administered by one of the authors, and no women refused to
respond to the questions.
These donors undergo a rigorous medical and psychosocial evaluation, with biological and
genetic tests. Once enrolled, they are prescribed 1 month of ovarian stimulation followed by
transvaginal ultrasound guided needle aspiration of their eggs for harvest, a procedure that
requires approximately 10–15 min of anaesthetic sedation. Women are free to drop out of
the programme at any time, and receive partial payment for the time dedicated. Full payment
follows the aspiration of eggs, regardless of the number harvested or the egg quality.
At the time of their presentation for either the initial screening interview or during a follow-
up visit, donors’ attitudes were surveyed with respect to stem cell research, and
compensation for participating in SCNT research. Donors (n = 230) were 26.2 ± 0.8 years
old; 100% were college educated; and 62% were Caucasian, 11% Hispanic, 10% Asian, 6%
African American and 11% mixed ethnicity. None had ever been enrolled in research as a
subject, and 36% had previously participated in at least one attempt at egg donation.
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Table 1 displays the results of the surveyed questions. Table 2 displays respondents’
answers concerning the minimum amount of compensation they felt necessary to undergo a
cycle of egg donation for purposes of stem cell research.
In brief, only 2% would provide services without payment. Approximately one-third would
participate for a smaller fee (US$8000) than that usually given to commercial donors as
compensation, while another third requested full payment. Although about half would prefer
to donate to reproductive rather than research purposes, the other half would not.
Discussion
This paper describes how efforts to recruit donors for HESC research without compensation
have not been successful, and how women donating oocytes for clinical purposes would
appear to be willing to do so for SCNT research as well, but feel that equivalent
compensation would be appropriate. Thus, failures to recruit women appear to result from
economics, not a lack of interest among potential donors, and can thus be addressed through
equity in payment.
Critics may argue that researchers have not spent enough time and effort trying to obtain
donations, and should first attempt to improve upon such efforts. That is not altogether
unreasonable. Additional time and effort, prior to implementation of additional
compensation, should be expended relatively swiftly and for a fixed and limited period.
These efforts and their results should be carefully documented, and information about them
made accessible such that they can be evaluated in a timely manner, so as not to unduly
delay beneficial stem cell research that might otherwise occur. Moreover, such efforts
should not in the meantime delay necessary consideration of the issues presented here. To
allow participants to decide whether they wish to have their eggs used for research and/or
reproductive purposes in fact maximizes their autonomy. Women’s preferences can be
respected, and they can be given options of whether to donate for research or not. Justice
dictates that payment of egg providers for stem cell research represents a non-discriminating
policy of allowing women of all backgrounds to freely participate in research that serves the
common good. Particularly as more states are considering and starting stem cell funding, it
is vital at least to consider these possibilities now, proactively.
Importantly, egg donors, undergoing the complex procedures involved, need assurance that
follow-up care will be provided, as necessary. Free medical care needs to be offered if
problems arise in the short, medium or long term. Currently, in many locales, egg donors for
reproductive purposes are often sought and paid if they have traits that couples seeking eggs
view as desirable (e.g. indicators of success, such as an Ivy League education). Hence, in
certain areas, poorer women may currently be excluded from such egg donation (although
empirical data on this possible phenomenon have not been published). For research
purposes, donation that offers compensation may lead to poorer women donating
proportionately more than at present. Thus, provisions for egg donation for research must
give special attention to ensuring that these women receive follow-up health care as needed.
In addition, if donation for research with compensation and appropriate free medical follow-
up occurs, healthcare providers will then increasingly face complex ethical questions. For
example, providers will have to decide what groups of women to target for recruitment, and
how. For example, physicians could focus on recruiting healthy paid donors versus perhaps
less healthy unpaid individuals who have, or are at risk for, diseases for which HESC
treatments may be developed, and who may thus be potential beneficiaries of the research.
Some critics may argue that because of the medical risks involved in donation, the latter
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group should be targeted more, since they may ultimately benefit more from the eventual
research. Similarly, certain critics may assert that these at-risk individuals should donate
without compensation, since these women and/or their family members may ultimately
benefit, and consequently other donors would not need to be paid. Yet, the potential benefits
of HESC research are not yet wholly clear, i.e., whether effective treatments will in fact be
developed, and if so, for what diseases. Unpaid donors face risks; and they and their families
may never in fact receive any benefit.
These data raise larger questions, too, of when, if ever, social benefits resulting from
scientific research should begin to be considered and possibly outweigh fears of potential
individual risks (e.g., of commodification or exploitation). In states, such as NY, where local
laws do not forbid payment, fairness dictates that such efforts should be made to permit
donations to move the science ahead. Thus, social benefits of research may need to be
weighed more heavily against countervailing concerns. Indeed, in countries that have
banned the compensation of egg donors, the number of achieved IVF cycles have greatly
diminished (Craft and Thornhill, 2005; Sauer, 2005). Hence, women have sought care
outside national borders (Spar, 2005).
Nevertheless, challenges may arise when cell lines that result from paid donors are then
exported and used in other states or countries that still prohibit payment. However, if in fact
voluntary donation is relatively unsuccessful in other states and countries, these other
political entities will presumably need to re-evaluate their current policies. Yet, governments
may arrive at somewhat differing policies that could still perhaps hamper inter-institutional
collaborations. Questions then emerge, too, of whether researchers will be forced to consider
moving to other states or countries in order to do their work.
The overseeing of egg providing must be vigilant, with an IRB, working with an ESCRO
Committee. Nevertheless, further guidelines need to be developed and refined to help
ESCRO Committees in addressing these issues. NAS guidelines are non-binding, and the
degree to which states and research institutions follow them is unknown. No research has yet
been published on whether ESCRO Committees vary, and if so, how. Anecdotally, some
ESCRO Committees do or will follow these guidelines ‘generally’, though deviating in
certain unclear ways. Further study of these differences could be enormously beneficial.
Some ESCRO Committees may opt to accept such cell lines under current policies, while
other ESCRO Committees may face pressures at their local institutions (e.g. if an
institutional hospital Chief Executive Officer personally opposes payments). Thus, bans
such as that of President Bush’s on national funding of HESC may have unintended adverse
consequences in creating ‘patchworks’ of differing policies, instead of centralized guidelines
and standards, impeding collaborations across political boundaries.
Regardless of the level of payment, IRB and ESCRO Committees, in adhering to the highest
possible standards, should carefully review and monitor recruitment processes and materials
(e.g. flyers and advertisements). Previous work indicates that in general, IRB do not screen
recruitment information adequately, and that despite federal guidelines, on-line recruitment
information, for example, is usually biased, presenting benefits with compensation, but not
risks or burdens (Klitzman et al., 2008).
To optimize policy, urgent needs also exist for research on payment practices. Thus,
researchers should investigate the impact of recruitment approaches on enrollment, e.g.
assessing the socioeconomic status of women who decide to provide eggs or not, the
medical and psychological impacts that providing oocytes has on donors, and the ways
ESCRO Committees approach and make decisions about these issues. Finally, if women
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receive compensation, they should then best be termed egg ‘providers’ rather than egg
‘donors’ per se.
In sum, the data presented here support the notion that oocyte donors should be fairly
compensated; and highlight critical needs for research and attention to examine the many
issues emerging in this new and rapidly evolving field.
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Table 1
Responses of donors (n = 230) to inquiries regarding stem cells and participation in providing gametes for
research.
In addition to using donor eggs for reproduction, eggs can also be used for medical
research such as seeking cures for cancer. Are you aware of this?
Yes No
52% 48%




Knowing that the process for donating eggs for research and for reproduction is the same,
would you be willing to donate your eggs for medical research?
Yes No Unsure
82% 13% 5%
In several States and various countries in the world, it is illegal to compensate donors who
want to donate eggs for medical research. Are you aware of this?
Yes No Unsure
38% 61% 1%
Do you think you should be compensated the same financially whether you are donating
eggs for reproduction or for research?
Yes No Unsure
74% 18% 8%
Financial compensation for egg donors may be limited when they are donating for
research purposes. If payment was limited to travel reimbursement only, would you still
consider donating your eggs?
Yes No Unsure
43% 51% 6%
Would you prefer to donate for research or to a reproductive couple? Research Reproductive couple No preference
9% 51% 40%
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Table 2
Survey questionnaire responses to question: knowing that the process when donating eggs for research and for
reproduction is the same, what minimum amount of money would be acceptable for you to agree to
participate? Response rate is percentage of total number 230.
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